Navigation Links
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Date:5/20/2008

Placebo-Controlled Study Results Published in May 20 Issue of Neurology

WOODCLIFF LAKE, N.J., May 20 /PRNewswire/ -- Eisai Corporation of North America announced today the publication of a placebo-controlled study in Neurology that found patients with Lennox-Gastaut syndrome (LGS) treated with the investigational antiepileptic agent rufinamide as adjunctive therapy experienced more than 40% fewer drop attacks than patients who received placebo (increase of 1.4%). The differences between rufinamide and placebo were observed as early as week two of the study. LGS is a severe form of generalized epilepsy that develops in early childhood and is characterized by multiple types of treatment-resistant seizures and high rates of seizure-related injury.

"Lennox-Gastaut syndrome is a devastating form of pediatric epilepsy usually resulting in multiple seizures occurring several times a day and is often associated with impaired mental development," said the study's lead author Tracy Glauser, MD, Director, Comprehensive Epilepsy Program, Cincinnati Children's Hospital Medical Center, Ohio. "Existing antiepileptics offer limited seizure control and there may be difficulties with tolerability."

Study Methods

The study was a multicenter, double-blind, placebo-controlled, randomized, parallel-group study. Male and female patients (between 4 and 30 years of age) were included if they had a diagnosis of inadequately controlled seizures associated with LGS (including both atypical absence seizures and drop attacks) and were being treated with 1 to 3 concomitant stable dose antiepileptic drugs (AEDs). Each patient must have had at least 90 seizures in the 28-day baseline period prior to study entry. One hundred thirty-nine eligible patients were randomized; 138 patients received either rufinamide (titrated up to 45mg/kg per day) (n=74) or placebo (n=64) in addition to their other AEDs.

The median percentage reduction in total seizure frequency fr
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Vermillion, Inc. (NASDAQ: VRML ... and women,s health, has appointed Holly B. Bauzon ... Ms. Bauzon has a proven track record ... for laboratory services companies. She has more than 20 ... where she held the position of Director, Lab Services ...
(Date:8/21/2014)... YORK , Aug. 21, 2014  Publicis Groupe ... Shannon Hartley , Managing Partner and Healthcare Industry Group ... PharmaVoice 100, which recognizes the most inspiring people in ... are leaders in research and development, marketing, technology, creativity, ... agency in 2006 as a partner in its leading ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... Development, LLC (JRD) announced today that the U.S. Food ... designation to the supplemental New Drug Application (sNDA) filed ... an oral anticoagulant, to reduce the risk of thrombotic ... The FDA grants Priority Review to medicines ...
... Feb. 27, 2012 With cold and flu season ... American Pharmacists Association (APhA) encourages patients to actively ... medications. Pharmacists are the most accessible health care provider ... best over-the-counter (OTC) medication for cold, flu and allergy ...
Cached Medicine Technology:U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 2Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 3Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 4
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... Market Research “Home Audio Equipment (Product Types - Home ... audio accessories) Market - Global Industry Analysis, Size, Share, ... was valued at USD 15.94 billion in 2012 and ... growing at a CAGR of 3.7% from 2013 to ...
(Date:8/21/2014)... 21, 2014 The Swedish-American Life ... conference will focus on the Future of Medicine ... innovation and commercialization. , With the mission to ... the worlds' of business and science. "Over the ... Summit, gathering a diverse community with representatives challenging ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... using sunscreen dropped nearly 12 percent in the last decade, ... the number of teens using indoor tanning beds barely decreased. ... risk of skin cancers, including deadly melanomas, the researchers noted. ... of teens who reported wearing sunscreen, from 67.7 percent in ...
(Date:8/21/2014)... August 21, 2014 The Onder Law ... product liability law, announces the launch of a new ... information on morcellator surgery lawsuits for cancer ... morcellator cancer warning and the July 2014 morcellator recall. ... April 17, 2014 FDA warning on morcellator surgery and ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
Breaking Medicine News(10 mins):Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... reporting successful application of the technology used in home ... make anticancer drugs like tamoxifen and paclitaxel dissolve more ... the disease. The process, described in ACS, journal, Langmuir, ... has potential for improving the performance of dyes, paints, ...
... PITTSBURGHUniversity of Pittsburgh researchers have recorded neuron activity ... biological root of the teenage propensity to consider ... more vulnerable to drug addiction, behavioral disorders, and ... the Journal of Neuroscience that electrode ...
... low socioeconomic status (SES) is associated with higher ... arthritis (RA). Statistically significant differences in race, public ... between depressed and non-depressed patients. Study findings are ... Care & Research , a journal published by ...
... 26 (HealthDay News) -- Hispanic seniors in the United ... be vaccinated against flu and pneumonia, a new study ... analyzed data from more than 244,000 seniors who took ... lifetime immunization rates for pneumonia were 74 percent for ...
... Staphylococcus aureus , the bacterium which is responsible for ... a strategy of hiding within host cells to escape ... The research, published by EMBO Molecular Medicine , ... their environmental conditions, lie dormant inside host cells and ...
... to 20 per cent of nurses and nursing students may ... tackling this difficult issue - and protecting public safety - ... message in a paper in the February issue of the ... recommended six key points that could be built into alternative-to-dismissal ...
Cached Medicine News:Health News:Pitt team finds teen brains over-process rewards, suggesting root of risky behavior, mental ills 2Health News:Low socioeconomic status increases depression risk in rheumatoid arthritis patients 2Health News:Research shows how pathogenic bacteria hide inside host cells 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 3
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively, right up until the definitive implants are to be put i...
Tibial distractor...
... PowerSuite™ holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Medicine Products: